Sporadic hypoparathyroidism treated with teriparatide: A case report and literature review

Experimental and Clinical Endocrinology and Diabetes

Volumn 115, Issue 1, 2007, Pages 50-54

  Angelopoulos, N G ^a   Goula, A ^b   Tolis, G ^a  

^a HIPPOKRATION HOSPITAL   (Greece)

^b AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

Author keywords

Calcitriol; Hypercalciuria; Hypocalcemia; Hypoparathyroidism; Synthetic human parathyroid hormone

Indexed keywords

CALCITRIOL; CALCIUM CARBONATE; HYDROCHLOROTHIAZIDE; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; THIAZIDE DIURETIC AGENT;

ABSENCE OF SIDE EFFECTS; ADULT; ANAMNESIS; ARTICLE; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CASE REPORT; CLINICAL FEATURE; DIET SUPPLEMENTATION; DRUG DOSE REDUCTION; FEMALE; HUMAN; HYPERCALCIURIA; HYPOPARATHYROIDISM; PHYSICAL EXAMINATION; PRIORITY JOURNAL;

ADULT; BONE DENSITY CONSERVATION AGENTS; CALCITRIOL; CALCIUM; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOPARATHYROIDISM; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; TERIPARATIDE;

EID: 33847103166     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-967088     Document Type: Article

References (28)

1. Abugassa S, Nordenstrom J, Eriksson S, Sjoden G: Bone mineral density in patients with chronic hypoparathyroidism. J Clin Endocrinol Metab 1993; 76: 1617-1621
2. Angelopoulos NG, Goula A, Rombopoulos G, Kaltzidou V, Katounda E, Kaltsas D, Tolis G: Hypoparathyroidism in transfusion-dependent patients with beta-thalassemia. J Bone Miner Metab 2006; 24: 138-145
3. Bellido T, Ali AA, Plotkin LI, Fu Q, Gubrij I, Roberson PK et al.: Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem 2003; 278: 50259-50272
4. Chan FK, Tiu SC, Choi KL, Choi CH, Kong AP, Shek CC: Increased bone mineral density in patients with chronic hypoparathyroidism. J Clin Endocrinol Metab 2003; 88: 3155-3159
5. Chen Q, Kaji H, Iu M, Nomura R, Sowa H, Yamauchi M, Tsukamoto T, Sugimoto T, Chihara K: Effects of an excess and a deficiency of endogenous parathyroid hormone on volumetric bone mineral density and bone geometry determined by peripheral quantitative computed tomography in female subjects. J Clin Endocrinol Metab 2003; 88: 4655-4658
6. Cheng PT, Chan C, Muller K: Cyclical treatment of osteopenic ovariectomized adult rats with PTH (1-34) and pamidronate. J Bone Miner Res 1995; 10: 119-126
7. Demiralp B, Chen H, Koh-Paige AJ, Keller ET, McCauley LK: Anabolic effects of parathyroid hormone during endochondral bone growth are dependent on c-fos. Endocrinology 2002; 143: 4038-4047
8. Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R: Anabolic actions of parathyroid hormone on bone. Endocr Rev 1993; 14: 690-709
9. Duan Y, De Luca V, Seeman E: Parathyroid hormone deficiency and excess: similar effects on trabecular bone but differing effects on cortical bone. J Clin Endocrinol Metab 1999; 84: 718-722
10. Eisenbarth GS, Gottlieb PA: Autoimmune polyendocrine syndromes. N Engl J Med 2004; 350: 2068-2079
11. Fujiyama K, Kiriyama T, Ito M: Attenuation of postmenopausal high turnover bone loss in patients with hypoparathyroidism. J Clin Endocrinol Metab 1995; 80: 2135-2138
12. Goswami R, Brown EM, Kochupillai N, Gupta N, Rani R, Kifor O, Chattopadhyay N: Prevalence of calcium sensing receptor autoantibodies in patients with sporadic idiopathic hypoparathyroidism. Eur J Endocrinol 2004; 150: 918
13. Hock JM, Gera I, Fonesca J, Raisz Human LG: PTH increases rat bone mass in ovariectomized and orchidectomized rats. Endocrinology 1998; 122: 2899-2904
14. Jiang Y, Zhao J, Eriksen EF, Wang O, Genant HK, Mitlak BH: Improved 3-dimensional microstructure of cancellous and cortical bone in a multicenter, double-blind, randomized and placebo controlled study of teriparatide [rhPTH(1-34)]. J Bone Miner Res 2002; 17 (Suppl 1):135
15. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC: Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999; 104: 439-446
16. Kruse K, Kracht U, Wohlfart K, Kruse U: Biochemical markers of bone turnover, intact serum parathyroid hormone and renal calcium excretion in patients with pseudohypoparathyroidism and hypoparathyroidism before and during vitamin D treatment. Eur J Pediatr 1989; 148: 535-539
17. Langdahl BL, Mortensen L, Vesterby A, Eriksen EF, Charles P: Bone histomorphometry in hypoparathyroid patients treated with vitamin D. Bone 1996; 18: 103-108
18. Li Y, Song YH, Rais N, Connor E, Schatz D, Muir A, Maclaren N: Autoantibodies to the extracellular domain of the calcium sensing receptor inpatients with acquired hypoparathyroidism. J Clin Invest 1996; 4: 910-914
19. Mayer A, Ploix C, Orgiazzi J, Desbos A, Moreira A, Vidal H, Monier JC, Bienvenu J, Fabien N: Calcium-sensing receptor autoantibodies are relevant markers of acquired hypoparathyroidism. J Clin Endocrinol Metab 2004; 89: 4484-4488
20. Miyakosni N, Kasukawa Y, Linkhart TA, Baylink DJ, Mohan S: Evidence that anabolic effects of PTH on bone require IGF-1 in growing mice. Endocrinology 2001; 142: 4349-4356
21. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH: Effect of parathyroid hormone 1-34 on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-1441
22. Polverosi R, Zambelli C, Sbeghen R: Calcification of the basal nuclei in hypoparathyroidism; the computed and magnetic resonance tomographic aspects. Radiol Med (Torino) 1994; 87: 512
23. Ruff RL, Weissmann J: Endocrine myopathies. Neurol Clin 1988; 6: 575-592
24. Sunthornthepvarakul T, Churesigaew S, Ngowngarmratana S: A novel mutation of the signal peptide of the preproparathyroid hormone gene associated with autosomal recessive familial isolated hypoparathyroidism. J Clin Endocrinol Metab 1999; 84: 3792-3796
25. Uusi-Rasi K, Beck TJ, Oreskovic TL, Sato M, Bogado CE, Zanchetta JR: Teriparatide (rhPTH[1-34]) improves the structural geometry of the hip. J Bone Miner Res 2002; 17 (Suppl 1):208
26. Winer KK, Yanovski JA, Cutler GB: Synthetic human parathyroid hormone 1-34 vs. calcitriol and calcium in the treatment of hypoparathyroidism: results of a randomized crossover trial. JAMA 1996; 276: 631-636
27. Winer KK, Yanovski JA, Sarani B, Cutler GB: A randomized, crossover trial of once daily vs. twice-daily human parathyroid hormone 1-34 in the treatment of hypoparathyroidism. J Clin Endocrinol Metab 1998; 83: 3480-3486
28. Winer KK, Ko CW, Reynolds JC, Dowdy K, Keil M, Peterson D, Gerber LH, McGarvey C, Cutler GB: Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone- (1-34) versus calcitriol and calcium. J Clin Endocrinol Metab 2003; 88: 4214-4220